| Literature DB >> 25653428 |
Suefen Kwa1, Shanmugalakshmi Sadagopal1, Xiaoying Shen2, Jung Joo Hong3, Sailaja Gangadhara1, Rahul Basu1, Blandine Victor1, Smita S Iyer1, Celia C LaBranche4, David C Montefiori4, Georgia D Tomaras2, Francois Villinger3, Bernard Moss5, Pamela A Kozlowski6, Rama Rao Amara7.
Abstract
Here, we show that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency virus (SIV) vaccine enhances protection against a pathogenic neutralization-resistant mucosal SIV infection, improves long-term viral control, and prevents AIDS. Analyses of serum IgG antibodies to linear peptides of SIV Env revealed a strong response to V2, with targeting of fewer epitopes in the immunodominant region of gp41 (gp41-ID) and the V1 region as a correlate for enhanced protection. Greater expansion of antiviral CD8 T cells in the gut correlated with long-term viral control.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25653428 PMCID: PMC4442387 DOI: 10.1128/JVI.03527-14
Source DB: PubMed Journal: J Virol ISSN: 0022-538X Impact factor: 5.103